KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Capital Leases (2020 - 2022)

Ginkgo Bioworks Holdings (DNA) has disclosed Capital Leases for 3 consecutive years, with $59.8 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Capital Leases rose 267.85% year-over-year to $59.8 million, compared with a TTM value of $59.8 million through Sep 2022, up 267.85%, and an annual FY2021 reading of $22.3 million, up 34.9% over the prior year.
  • Capital Leases was $59.8 million for Q3 2022 at Ginkgo Bioworks Holdings, up from $51.5 million in the prior quarter.
  • Across five years, Capital Leases topped out at $59.8 million in Q3 2022 and bottomed at $16.3 million in Q3 2021.
  • Average Capital Leases over 3 years is $32.3 million, with a median of $24.8 million recorded in 2021.
  • The sharpest move saw Capital Leases skyrocketed 34.9% in 2021, then surged 267.85% in 2022.
  • Year by year, Capital Leases stood at $16.5 million in 2020, then skyrocketed by 34.9% to $22.3 million in 2021, then skyrocketed by 168.55% to $59.8 million in 2022.
  • Business Quant data shows Capital Leases for DNA at $59.8 million in Q3 2022, $51.5 million in Q2 2022, and $27.3 million in Q1 2022.